Vitrafy advances U.S. platelet program as demand for cryopreservation tech builds

The latest announcement is out from Vitrafy Life Sciences Ltd. ( (AU:VFY) ).

Vitrafy Life Sciences reported strong progress in the third quarter of FY2026, highlighted by completion of Phase II platelet cryopreservation trials with the U.S. Army Institute of Surgical Research. The study showed Vitrafy’s simplified “no-wash” protocol delivered post-thaw platelet quality well above current regulatory standards, positioning the technology as a differentiated option in a market with no comparable FDA-approved solution.

The company is leveraging these results to deepen commercial engagement across U.S. civilian and military blood networks, supported by growing demand for demonstrations at its new U.S. site and an industry shift away from legacy red blood cell technologies. Vitrafy also advanced its partnership with animal health group IMV, ramped device manufacturing with initial units deployed in France and the U.S., and continued groundwork toward FDA device registration for its Guardion system, while building early-stage opportunities in cell and gene therapy.

The most recent analyst rating on (AU:VFY) stock is a Buy with a A$2.40 price target. To see the full list of analyst forecasts on Vitrafy Life Sciences Ltd. stock, see the AU:VFY Stock Forecast page.

More about Vitrafy Life Sciences Ltd.

Vitrafy Life Sciences Limited is an Australian life sciences company specializing in advanced cryopreservation technologies, with a focus on blood components and cell-based products. Its solutions target human health markets including military and civilian blood networks, as well as the emerging cell and gene therapy sector, where it aims to enhance product quality, availability and supply chain resilience.

Average Trading Volume: 21,511

Technical Sentiment Signal: Buy

Current Market Cap: A$122.6M

Learn more about VFY stock on TipRanks’ Stock Analysis page.